000 01236 a2200313 4500
005 20250513112810.0
264 0 _c19970326
008 199703s 0 0 eng d
022 _a0007-1331
024 7 _a10.1046/j.1464-410x.1997.06310.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKreis, W
245 0 0 _aUnique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.
_h[electronic resource]
260 _bBritish journal of urology
_cFeb 1997
300 _a196-202 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAntineoplastic Agents, Hormonal
_xantagonists & inhibitors
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xantagonists & inhibitors
650 0 4 _aDrug Synergism
650 0 4 _aEstramustine
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aProstatic Neoplasms
_xdrug therapy
650 0 4 _aTumor Cells, Cultured
700 1 _aBudman, D R
700 1 _aCalabro, A
773 0 _tBritish journal of urology
_gvol. 79
_gno. 2
_gp. 196-202
856 4 0 _uhttps://doi.org/10.1046/j.1464-410x.1997.06310.x
_zAvailable from publisher's website
999 _c9040632
_d9040632